Melbourne, April 24, 2008 AEST (ABN Newswire) - Starpharma Holdings Ltd (ASX: SPL)(OTCQX: SPHRY) has been advised that all of the Company's shares held by ANZ pursuant to stock lending arrangements associated with the Opes Prime Group have now been sold in an orderly fashion.
The company understands that the majority of the shares were purchased on market by two existing institutional investors, with the balance of 678,334 shares taken up by Deputy Chairman Dr John Raff.
Starpharma CEO Dr Jackie Fairley said: "We are pleased to have this situation resolved promptly with no impact on the Company's operations, and it is particularly pleasing to see such strong support from existing investors. We look forward to continuing to build upon the recent successes which include announcements regarding HPV activity for VivaGel(R), the EMD Merck launch of Priostar(R) transfection reagent kit, and an agreement with Unilever."
Contact
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
Ben Rogers
Company Secretary
+61 3 8532 2702
ben.rogers@starpharma.com
| ||
|